 |
|
|
| |
OMBITASVIR/PARITAPREVIR/R, DASABUVIR, AND SOFOSBUVIR TREATMENT OF PATIENTS WITH HCV GENOTYPE 1-INFECTION WHO FAILED A PRIOR COURSE OF DAA THERAPY: THE QUARTZ-I STUDY....95-100% SVR
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-27 Barcelona
Fred Poordad* 1, Michael Bennett2, Thomas E. Sepe3, Eric Cohen4, Robert W. Reindollar5, Gregory Everson6, Raymond W. Phillips7, Asma Siddique8, J. Greg Sullivan9, Terry D. Box10, Bo Fu4, Tami Pilot-Matias4, Manal Abunimeh4, Daniel E. Cohen4, Ziad Younes11
1The Texas Liver Institute/University of Texas Health Science Center, San Antonio, 2Medical Associates Research Group, San Diego, 3Liver Center, University Gastroenterology, Providence, 4AbbVie Inc., North Chicago, 5Piedmont Healthcare/Carolinas Center for Liver Disease, Statesville, 6University of Colorado Denver School of Medicine, Aurora, 7Gastroenterology Group of Naples PA, Naples, 8Virginia Mason Hospital and Medical Center, Seattle, 9Parkway Medical Center, Birmingham, 10Clinical Research Centers of America, Murray, 11GastroOne, Germantown, United States
|
| |
|
|
|
|
|
